Your browser doesn't support javascript.
loading
Structure-Activity Relationship of para-Carborane Selective Estrogen Receptor ß Agonists.
Sedlák, David; Wilson, Tyler A; Tjarks, Werner; Radomska, Hanna S; Wang, Hongyan; Kolla, Jayaprakash Narayana; Lesnikowski, Zbigniew J; Spicáková, Alena; Ali, Tehane; Ishita, Keisuke; Rakotondraibe, Liva Harinantenaina; Vibhute, Sandip; Wang, Dasheng; Anzenbacher, Pavel; Bennett, Chad; Bartunek, Petr; Coss, Christopher C.
Afiliação
  • Sedlák D; CZ-OPENSCREEN, Institute of Molecular Genetics of the Czech Academy of Sciences, Vídenská 1083, 142 20 Prague, Czech Republic.
  • Wilson TA; Medicinal Chemistry Shared Resource, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, United States.
  • Tjarks W; Division of Medicinal Chemistry and Pharmacognosy College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States.
  • Radomska HS; Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States.
  • Wang H; Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States.
  • Kolla JN; CZ-OPENSCREEN, Institute of Molecular Genetics of the Czech Academy of Sciences, Vídenská 1083, 142 20 Prague, Czech Republic.
  • Lesnikowski ZJ; Laboratory of Medicinal Chemistry, Institute of Medical Biology PAS, 106 Lodowa Street, 93-232 Lodz, Poland.
  • Spicáková A; Department of Pharmacology, Faculty of Medicine, Palacky University, Hnevotínská 3, 77515 Olomouc, Czech Republic.
  • Ali T; Division of Medicinal Chemistry and Pharmacognosy College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States.
  • Ishita K; Division of Medicinal Chemistry and Pharmacognosy College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States.
  • Rakotondraibe LH; Division of Medicinal Chemistry and Pharmacognosy College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States.
  • Vibhute S; Medicinal Chemistry Shared Resource, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, United States.
  • Wang D; Medicinal Chemistry Shared Resource, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, United States.
  • Anzenbacher P; Department of Pharmacology, Faculty of Medicine, Palacky University, Hnevotínská 3, 77515 Olomouc, Czech Republic.
  • Bennett C; Medicinal Chemistry Shared Resource, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, United States.
  • Bartunek P; Drug Development Institute, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, United States.
  • Coss CC; CZ-OPENSCREEN, Institute of Molecular Genetics of the Czech Academy of Sciences, Vídenská 1083, 142 20 Prague, Czech Republic.
J Med Chem ; 64(13): 9330-9353, 2021 07 08.
Article em En | MEDLINE | ID: mdl-34181409
ABSTRACT
Selective agonism of the estrogen receptor (ER) subtypes, ERα and ERß, has historically been difficult to achieve due to the high degree of ligand-binding domain structural similarity. Multiple efforts have focused on the use of classical organic scaffolds to model 17ß-estradiol geometry in the design of ERß selective agonists, with several proceeding to various stages of clinical development. Carborane scaffolds offer many unique advantages including the potential for novel ligand/receptor interactions but remain relatively unexplored. We synthesized a series of para-carborane estrogen receptor agonists revealing an ERß selective structure-activity relationship. We report ERß agonists with low nanomolar potency, greater than 200-fold selectivity for ERß over ERα, limited off-target activity against other nuclear receptors, and only sparse CYP450 inhibition at very high micromolar concentrations. The pharmacological properties of our para-carborane ERß selective agonists measure favorably against clinically developed ERß agonists and support further evaluation of carborane-based selective estrogen receptor modulators.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Compostos de Boro / Receptor beta de Estrogênio / Estrogênios Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Compostos de Boro / Receptor beta de Estrogênio / Estrogênios Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article